Ciprofibrate (Synonyms: Win35833)

Cat. No.: HY-B0664 Purity: 99.90%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias.

For research use only. We do not sell to patients.

Ciprofibrate Chemical Structure

CAS No. : 52214-84-3

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 125	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Ciprofibrate:

Ciprofibrate (Standard) Get quote
Ciprofibrate-d₆ Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

Biological Activity
Purity & Documentation
References
Customer Review

Description

Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha^[1]. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias^[2].

IC₅₀ & Target^[1]

PPARα

In Vitro

Ciprofibrate (500 μM; 4 hours) increases the PPARa phosphorylation level in rat Fao cells^[1].
In a LucLite assay, Ciprofibrate (10-100μM; 24 hours) induces PPARR activation by existing increased LUC activities in the rat liver H4IIEC3 cells transfected with PPRE-AB LUC reporter gene plasmid^[2].
Ciprofibrate (10-100 μM; 24 hours) is not cytotoxic for HepG2 cells, and the cell viability is 99.7%^[3].
Ciprofibrate (100 μM; 24 hours) also abolishes FFAs mixture-induced lipid deposition and decreases FFAs mixture-increased TG contents in HepG2 cells^[3].
Ciprofibrate (100 μM; 24 hours) almost entirely eliminates the FFAs mixture-induced inflammatory cytokines overproduction, including MCP-1, TNF-α, and IL-6 in HepG2 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ciprofibrate (oral administration; 10 mg/kg/day; 3 days) does not result in any significant effects on body weight or absolute liver weight for MCD diet-fed mice. Ciprofibrate improves hepatic steatosis and reduced hepatic necro-inflammation in MCD diet-fed mice. It also reduced hepatic cytokine protein and mRNA levels (MCP-1, TNFα and IL-6) as compared to those of choline-deficient (MCD) diet-fed mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (six-week-old males)^[3]
Dosage:	10 mg/kg
Administration:	Oral administration; 10 mg/kg/day; 3 days
Result:	Decreased MCD diet-resulted hepatic steatosis and hepatic necro-inflammation in mice.

Clinical Trial

Molecular Weight

289.15

Formula

C₁₃H₁₄Cl₂O₃

CAS No.

52214-84-3

Appearance

Solid

Color

White to off-white

SMILES

CC(C)(OC1=CC=C(C2C(Cl)(Cl)C2)C=C1)C(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (345.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4584 mL	17.2921 mL	34.5841 mL
5 mM	0.6917 mL	3.4584 mL	6.9168 mL
10 mM	0.3458 mL	1.7292 mL	3.4584 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.90%

Select Batch:

Data Sheet (273 KB) SDS (0 KB)

COA (245 KB) HNMR (247 KB) RP-HPLC (245 KB) LCMS (89 KB)

Handling Instructions (2659 KB)

References

[1]. Passilly, P., et al., Phosphorylation of peroxisome proliferator-activated receptor alpha in rat Fao cells and stimulation by ciprofibrate. Biochem Pharmacol, 1999. 58(6): p. 1001-8. [Content Brief]

[2]. Agnes M Rimando, et al. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem. 2005 May 4;53(9):3403-7. [Content Brief]

[3]. Thing-Fong Tzeng, et al. 6-gingerol protects against nutritional steatohepatitis by regulating key genes related to inflammation and lipid metabolism. Nutrients. 2015 Feb 4;7(2):999-1020. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.4584 mL	17.2921 mL	34.5841 mL	86.4603 mL
	5 mM	0.6917 mL	3.4584 mL	6.9168 mL	17.2921 mL
	10 mM	0.3458 mL	1.7292 mL	3.4584 mL	8.6460 mL
	15 mM	0.2306 mL	1.1528 mL	2.3056 mL	5.7640 mL
	20 mM	0.1729 mL	0.8646 mL	1.7292 mL	4.3230 mL
	25 mM	0.1383 mL	0.6917 mL	1.3834 mL	3.4584 mL
	30 mM	0.1153 mL	0.5764 mL	1.1528 mL	2.8820 mL
	40 mM	0.0865 mL	0.4323 mL	0.8646 mL	2.1615 mL
	50 mM	0.0692 mL	0.3458 mL	0.6917 mL	1.7292 mL
	60 mM	0.0576 mL	0.2882 mL	0.5764 mL	1.4410 mL
	80 mM	0.0432 mL	0.2162 mL	0.4323 mL	1.0808 mL
	100 mM	0.0346 mL	0.1729 mL	0.3458 mL	0.8646 mL

Ciprofibrate Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ciprofibrate52214-84-3Win35833Win 35833Win-35833PPARPeroxisome proliferator-activated receptorsperoxisomeproliferatorhypolipidaemic hyperlipidaemias PPARalphaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks